An Interview with Carol Weil about the COMET Study, an ancillary study of NCI-MATCH. Its purpose is to test whether educating participants about genetic testing will increase their knowledge and reduce their stress after they receive results of tumor profiling tests.
Results from an early clinical trial suggests that a new method of preparing immune cells may lead to a potential treatment option for some patients with acute myeloid leukemia (also known as AML).
If you have ideas on how NCI can improve the clinical trials search form, we'd love to hear from you! Visit the feedback form on our clinical trials search page to share your ideas.
Clinical Trials Information for Patients and Caregivers
Placebos are rarely used in clinical trials of new cancer treatments. Learn about the limited role that placebos may play in some cancer clinical trials.
Designing and running clinical trials require the skills of many different types of experts. Learn about the typical roles and responsibilities of clinical trial team members.
The NCI Retinoblastoma Follow-up Study team is seeking people who took part in this study as children. The team is trying to reach patients who were diagnosed with retinoblastoma and treated in New York or Boston, especially between 1984 and 2006.
Lung-MAP is for patients with advanced squamous cell lung cancer that has not responded or has stopped responding to standard treatment. In this study, patients will be assigned to substudies based on genetic changes in their tumors.
This phase 1 trial is for patients with HPV-16-positive cervical, vulvar, penile, anal, or oropharyngeal cancers that have spread, come back, or gotten worse after treatment. The purpose is to study the side effects and find the best dose of T-cell receptor gene therapy when given together with pembrolizumab.
